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Abstract
Aims The aim of this study was to determine prognostic
factors in patients operated on for well-differentiated thyroid
cancer (WDTC).
Patients and methods A retrospective cohort study of
patients with WDTC treated at our institution between
1989 and 1991 (n097; mean age 52.3 years, 78 females,
follow-up 124.6±75.1 months) was made. Multivariate
analysis was performed including: age, gender, size of pri-
mary tumor, location and number of foci in thyroid tissue,
clinical stage, thyroid capsule infiltration, tumor histological
type, extent of surgery, prognosis based on the AGES and
MACIS scores, and tumor proliferative activity based on
determination of proliferating cell nuclear antigen (PCNA)
and Ki-67 expression in tumor tissue and nodal metastases.
Results The multivariate analysis showed increased relative
risk (RR) of death for: age above 60 years (7.39; p<0.001),
pTm (2.94; p00.002), pT3 (11.83; p<0.001), and pN1
(4.11; p<0.001). Total thyroidectomy decreased RR of
death (0.39; p00.023) when compared to more limited
resections. Moderate and high PCNA index was associated
with 48.3% and 87.5% mortality, respectively, while Ki-67
index was associated with the highest mortality rate (76%)
in the group of medium values.
Conclusions Despite good prognosis in WDTC, factors that
most significantly affect overall survival rate include age,
size of primary lesion and multifocal disease, presence of
nodal metastases, and extent of primary surgery.
Keywords Well-differentiatedthyroidcancer.Relativerisk
ofdeath.Totalthyroidectomy
Introduction
Thyroid cancer accounts for only 1% of all malignancies, yet
it is the most common endocrine tumor. Over the past two
decades, the incidence of thyroid cancer has increased four-
fold in females and threefold in males. Although well-
differentiated thyroid cancer (WDTC) is associated with a
good prognosis, in a certain group of patients it may have a
fatal outcome. Early detection of lesions, selection of optimal
surgical treatment in referral centers, target-oriented adjuvant
therapy, and treatment monitoring significantly improve ther-
apeutic results and quality of life in these patients [1, 2].
A group of WDTC patients with a poor prognosis may be
selectedfollowingdiagnosisestablishment,whatshouldaffect
further modificationoftreatment. The aim ofthisstudy wasto
determine prognostic factors in patients operated on for
WDTC at a single institution in a 20-year follow-up.
Materials and methods
A retrospective cohort study of 97 patients treated surgically
due to thyroid cancer in a single institution in the years 1989–
1991 was made. The mean age of the patients was 52.3 years
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istics of the investigated group are presented in Table 1.
Clinical stage was assessed using the seventh edition of the
TNM staging system (2010) and histopathological results
Table 1 General characteristics
of patients operated on the years
1989–1991
Investigated group 1989–1991
Age (years) n097
Mean (SD) 52.3 (15.5)
Gender [n (%)]
F/M 79 (81.4):18 (18.6)
Surgery—total resection [n (%)]
Yes/no 18 (18.6):79 (81.4)
Number of examined lymph nodes [n (%)] n095
0 73 (76.8)
1–5 17 (17.9)
6–10 4 (4.2)
>10 1 (1.1)
Number of involved lymph nodes [n (%)] n095
0 74 (77.9)
1–5 20 (21.1)
6–10 1 (1.1)
>10 0
Percentage of involved lymph nodes as compared to
number of examined lymph nodes
n022
Mean (SD) 74.7% (30.5%)
Histopathology [n (%)]
Follicular cancer 28 (28.9)
Papillary cancer 50 (51.6)
Oncocytic tumor (Hurthle cell carcinoma) 11 (11.4)
Partial papillary–follicular–undifferentiated thyroid cancer 8 (8.3)
Tumor size (mm) n091
Mean (SD) 40.0 (26.9)
Number of foci [n (%)] n097
1 73 (75.3)
2 15 (15.5)
>2 4 (4.2)
Diffuse form (involving entire parenchyma) 5 (5.2)
Capsular infiltration [n (%)] 59 (60.8)
MACIS n094
Mean (SD) 6.4 (2.2)
MACIS [n (%)]
Up to 5.99 42 (44.7)
6.00–6.99 15 (16.0)
7.00–7.99 16 (17.0)
8.00 and above 21 (22.3)
AGES n094
Mean (SD) 4.9 (2.9)
AGES [n (%)]
Up to 3.99 36 (38.3)
4.00–4.99 16 (17.0)
5.00–5.99 8 (8.5)
6.00 and above 34 (36.2)
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of examinations of materials stored in Hospital Records
Department.
While analyzing the extent of primary surgical pro-
cedures, the authors adopted a simple division to total
and subtotal thyroidectomies (total resection, subtotal
resection, Dunhill’s procedure, and thyroid lobectomy
with isthmectomy).
The analysis also included the extent of lymphatic system
resection, determining the number of examined lymph
nodes, number of involved lymph nodes, and the percentage
of involved lymph nodes among examined lymph nodes.
Assessment of death risk was based on two prognostic
scales: AGES (age, histologic grade, extrathyroid invasion
and distant metastasis, size of the primary lesion) and
MACIS (metastasis, age, completeness of resection, inva-
sion, size).
The presence and expression of proliferative antigens
proliferating cell nuclear antigen (PCNA) and Ki-67 were
investigated by immunocytochemical methods using mono-
clonal antibodies. To determine PCNA, monoclonal mouse
anti-PCNA antibodies (DAKO M 879) were used. Ki-67
antigen was determined based on monoclonal antibodies
(Monoclonal Mouse Anti Human Ki-67—DAKO).
Statistical analysis
The multivariate analysis was performed including: age,
gender, size of primary tumor, location and number of foci
in thyroid tissue, clinical stage, thyroid capsule infiltration,
tumor histological type, extent of surgery, prognosis based
on the AGES and MACIS scores, and tumor proliferative
activity based on determination of PCNA and Ki-67 expres-
sion in tumor tissue and nodal metastases. For quantitative
variables (age, mean thyroid volume, percentage of in-
volved lymph nodes among investigated nodes, and com-
parison of mean follow-up), as the first step of the analysis,
the conformity to normal distribution was assessed by the
Shapiro–Wilk test. In variables with normal distribution,
comparisons were made using the Student’s t test. In varia-
bles with oblique distribution, significance of differences
was determined by the Mann–Whitney test.
The analysis also included the way particular clinical and
demographic properties affected survival of thyroid cancer
patients. Thus, the Kaplan–Meier curves were plotted to illus-
trate cumulative survival ratios in defined patient groups. To
determine death risk in defined patient groups, the authors
employed the Cox proportional regression model.
To determine independent death predictors in patients
operated on for thyroid cancer, the stepwise Cox regression
model was used. The criterion of a variable inclusion to the
model was p<0.05.
Results
The most common histological form was papillary carcinoma,
accounting for slightly more than one half (51.6%) of patients
operatedonintheperiod1989–1991andfollowedbyfollicular
cancer (28.9%) and other thyroid cancers (19.5%). The mean
size of a single tumor was 35 mm, although in a large number
of cases, lesions involved almost the entire thyroid lobe. Large
numbers of patients demonstrated high clinical stages, with a
relatively high percentage of stage III (25.8%) and stages IVa–
IVc (14.4%). A larger percentage of patients had higher scores
both according to MACIS (67.0%) and AGES (62.1%), what
was associated with a potentially poorer prognosis.
In the years 1989–1991, subtotal thyroidectomies were
predominant (81.4%). In 76.8% of cN0 patients, no lym-
phadenectomies were performed; the remaining 23.2%
showed nodal metastases pN1. Only 3.2% were subjected
to adjuvant radioiodine therapy.
In the investigated group, the mortality rate was 52.1%
(49/94 patients) over a mean follow-up of 124.6±
75.1 months. Mortality was found to increase with age. In
the group <50 years, its value was only 12.1%, while among
patients aged 60 and above—as much as 43.8% (Fig. 1). In
the oldest age group, the death risk increased more than
sevenfold as compared to patients below 50 years of age
(p<0.001). p value of the survival ratio at 7, 10, and 20-year
time point in age groups were statistically significant:
7 years, p00.022; 10 years, p<0.001; 20 years, p<0.001.
No significant risk was noted in association with gender
and survival curves. However, patients with multiple lesions
showed almost twofold mortality (approximately 43%) and
death risk increased almost threefold.
The analysis included death risk depending on TNM can-
cerstage.Atthetimeofsurgery,theinvestigatedgroupdidnot
include patientswith distant metastases (M0). With increasing
size of primary tumors (T), mortality rates increased (from
4.8% for T1 to 52.5% for T3–T4). Patients staged as at least
T3 showed an almost 11-fold increase of death risk as com-
pared to T1 patients (p<0.001). Death risk was significantly
higher in all patients with tumors above 40 mm in size (p<
0.001). N1 patients showed a more than fourfold higher death
risk (p<0.001). In patients with 1–5 nodes involved, death
riskincreasedmorethantwice(Fig.2).Nofurthereffectofthe
number of involved lymph nodes on survival was seen. In
patients with thyroid capsular infiltration, death risk increased
more than twofold, while mortality increased from 16.9% (no
capsular infiltration) to 30.6% (capsular infiltration) at a com-
parable follow-up. Death risk in stage II patients increased
more than fourfold as compared to stage 1, and more than 50-
fold in stage IV (p<0.001;Fig.3).
Total thyroidectomy decreased death risk by approximately
60% and intergroup differences were still marked 10 years
postoperatively (Fig. 4). Local relapses were noted in 12.4%.
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development. Death risk based on MACIS and AGES scores
pronouncedly increased, 25-fold and 20-fold, respectively
(sevenfoldto25-fold)withincreasingclinicalstage(p<0.001).
Analysis of survival as referred to PCNA and Ki-67
markers level showed the best prognosis in patients with low
PCNA indices (72.7% survived); poorer results were seen in
patientswithmediumPCNAindices—51.5%,andthepoorest
prognosis characterized patients with the highest indices (sur-
vival ofonly12.5%;p<0.001). The largestgroup consisted of
patients with low Ki-67 indices (78%), and there, 40% of
deaths were seen. The poorest prognosis and 100% mortality
were observed in patients with high Ki-67 indices, yet the
small number of subjects did not allow for drawing valid
conclusions. However, in the investigated WDTC population,
lymph node metastases were found not to be correlated with
values of cell proliferation antigen indices.
Using the stepwise Cox regression model, where all the
above variables were regarded as potential predictors, the
authors noted that factors that significantly and irrespec-
tively, of other variables, affected death risk were age and
lymph node metastases. Having taken into consideration the
confounding effect of age, metastases, clinical stage accord-
ing to prognostic scales, and tumor grade measured by cell
proliferation antigen indices, the authors found that total
resections decreased death risk by 77%.
Cumulative proportion of surviving patients in TNM categories 
lymph nodes (N) classification (Kaplan-Meier plots)
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Fig. 2 Kaplan–Meier
cumulative survival ratios in
TNM classification groups—N
Cumulative proportion of surviving patients in age groups 
(Kaplan-Meier plots)
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cumulative survival ratios in
age groups
812 Langenbecks Arch Surg (2012) 397:809–815Discussion
The presented material includes patients treated in a single
center within a defined time and analyzed over a 20-year
follow-up period. Mortality was found to increase with age.
All clinical observations to date confirm the above opinion,
yet they do not explain the causes of the phenomenon. In
adult population, death risk due to WDTC increases with
age both in females and males. Elderly patients are com-
monly diagnosed with higher stage tumors, of more aggres-
sive histology, often with WDTC dedifferentiation to poorly
differentiated forms.
In keeping with multistage carcinogenesis theory, various
phenotype variant of thyroid tumors may develop due to
genetic defects of signaling cascade through oncogene activa-
tionandinactivationandconsecutivemutations.Presently,the
best understood form of such transformations is the theory of
anaplastic carcinoma developing in a WDTC background [3,
4]. Moreover, poorer therapeutic results in elderly patients are
associated with their deteriorated general state (concomitant
diseases) and poorer treatment tolerance. Similar correlations
have been demonstrated for prostate cancer and breast cancer
[5]. Assessing the relation between age and cancer develop-
ment, one must also take into consideration an increased
Cumulative proportion of surviving patients in clinical stage categories 
(Kaplan-Meier plots)
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Fig. 3 Kaplan–Meier
cumulative survival ratios in
clinical stage groups
Cumulative proportion of surviving patients in thyroidectomy categories
(Kaplan-Meier plots)
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for passing through particular carcinogenesis stages with mo-
lecular changes allowing for cell dedifferentiation, and
carcinogenesis-favoring environmental changes combined
with poor availability and quality of screening tests [6–8].
The effect of gender on the course of treatment in WDTC
patients seems to be a somewhat controversial prognostic
factor. Nevertheless, gender is present in all currently
employed prognostic systems. A higher incidence of nodular
lesions in female population is not identical with a percent
increase of diagnosed malignancies. An almost twofold pre-
dominance of malignant thyroid lesions in a background of
cold nodules was demonstrated in male population [9].
In the report of Sciuto et al., of more than 1,500 patients,
approximately 80% were women.Of 37mortalities,19deaths
were noted in males [10]. Some authors suggest that a poorer
prognosis in thyroid cancer in males as compared to females
results from lack of a cytoprotective role played by estrogens,
indicating that when menopausal disturbances develop, thy-
roid cancer morbidity in the population increases accompa-
nied by an increase in the number of forms associated with
poorer prognosis [11]. Nevertheless, there are also numerous
reports that contradict the above observations and point to
similar late therapeutic results in differentiated thyroid can-
cers, regardless of gender [12, 13]. Based on the present
analysis, the authors did not observe a significant risk of
statistically significant differences in survival curves plotted
for males and females.
A thorough analysis of the relation between the primary
focus size and increased death risk showed that risk values
were significant for all patients with tumors sized above
40 mm. Survival curves showed that patients with tumors
above 40 mm died markedly sooner and mortality rates were
higher.
Primary tumors up to 1 cm in size are associated with a
good prognosis, but they may have all the specific properties
of malignant tumors, with nodal metastases, capsular infiltra-
tion, or multifocal growth in thyroid tissue. So et al. analyzed
551 patients with papillary thyroid carcinoma, including 203
patients with microcarcinomas. The latter showed as many as
31% of multifocal cancer with nodal metastases in approxi-
mately 24.6% and capsular infiltrations in 20.7% patients. We
should thus assume that one fourth of patients, despite diag-
nosed thyroid papillary microcarcinomas, showed all the
properties of fully symptomatic disease. The primary focus
size was immaterial in patients with asymptomatic metastases
to medial compartment lymph nodes [14–18].
Machens et al. observed that both multifocality (23.5%)
and nodal metastases (40.2%) were markedly more common
in females with papillary thyroid cancer in tumors up to
2 cm in diameter, while lesions above 20 mm more com-
monly gave distant metastases in patients with follicular
thyroid carcinoma [19, 20]. The analysis of Bilimoria et al.
showed in a very large population of thyroid papillary
cancer patients in a 10-year follow-up that tumors above
1 cm in diameter were apt to relapse as much as five times
more often as compared to smaller tumors [21].
In their retrospective analysis, Scheumann et al. found
that routine resection of central compartment lymph nodes
positively (p<0.005) affected late survival and possibility of
T1–T3 tumor relapses. According to the 2010 TNM classi-
fication, the above was true for tumors above 1 cm in
diameter. The results could not have been unambiguously
addressed due to lack of a control group without central
compartment lymph nodes resection [22]. Thus, primary
tumors above 1 cm in diameter, with a multifocal growth
pattern in the form of intrathyroid lesions with numerous
primary foci and capsular infiltration are associated with a
poorer prognosis, especially in patients above 45 years of
life, being associated with higher proneness to local relapses
and distant metastases [23, 24].
Summing up the present analysis, it should be empha-
sized that factors that significantly and independently, of
other variables, affected death risk were age and nodal
metastases. Having taken into consideration the confound-
ing effect of age, metastases, clinical stage according to
prognostic scales, and tumor grade measured by cell prolif-
eration antigen indices, the authors found that total resec-
tions decreased death risk by 77%.
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